Completed PHASE3 INTERVENTIONAL 2-arm NCT00350636

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension

Sponsor: Watson Pharmaceuticals

Conditions Overactive Bladder

Interventions Oxybutynin topical gel Placebo topical gel

Updated 7 times since 2017 Last updated: Apr 13, 2010 Started: Jun 30, 2006 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00350636, this PHASE3 trial focuses on Overactive Bladder and remains completed. Sponsored by Watson Pharmaceuticals, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Watson Pharmaceuticals

Data source: Watson Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Allentown, United States , Alpharetta, United States , Anaheim, United States , Atlanta, United States , Austin, United States , Aventura, United States , Belville, United States , Bethany, United States and 53 more locations